Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025).

The new TRISCEND II trial data presented today during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system and showed:

  • Significant and sustained near elimination of tricuspid regurgitation (TR);
  • Improvements in health status and quality of life;
  • No added device-related risk; and
  • Significantly lower all-cause mortality when accounting for patient crossover.